Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% starpharma LTD 7013 gel (vivagel) to assess expanded safety

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 2, 2012, Pages 134-140

  Moscicki, Anna Barbara ^a   Kaul, Rupert ^b   Yifei, M A ^a   Scott, Mark E ^a   Daud, Ibrahim I ^c   Bukusi, Elizabeth A ^c   Shiboski, Stephen ^a   Rebbapragada, Anuradha ^b   Huibner, Sanja ^b   Cohen, Craig R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Mucosal immune markers; Vaginal microbicide

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; LTD 7013; PLACEBO; UNCLASSIFIED DRUG; VIVAGEL;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MUCOSAL IMMUNITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CYTOLOGY;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CERVIX MUCUS; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; KENYA; POLYLYSINE; REGRESSION ANALYSIS; T-LYMPHOCYTES; UNITED STATES;

EID: 84857033178     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823f2aeb     Document Type: Article

References (24)

1. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002; 360: 971-977. (Pubitemid 35284107)
2. Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol. 2008; 59: 44-54. (Pubitemid 350285582)
3. Galen BT, Martin AP, Hazrati E, et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis. 2007; 195: 1332-1339. (Pubitemid 46649620)
4. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol- 9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis. 2001; 184: 418-428. (Pubitemid 32718505)
5. Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004; 71: 761-769. (Pubitemid 39108635)
6. Cohen CR, Brown J, Moscicki AB, et al. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One. 2011; 6: e16258. PMCID: PMC3024437.
7. McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MTN-004). AIDS. 2011; 25: 1057-1064. PMCID: PMC3103767.
8. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991; 29: 297-301.
9. Cohen CR, Moscicki AB, Scott ME, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS. 2010; 24: 2069-2074.
10. Cone RA, Hoen T, Wong X, et al. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis. 2006; 6: 90.
11. Mitchell J, Dimov V, Townley RG. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr Opin Investig Drugs. 2010; 11: 527-534.
12. Mordvinov VA, Sanderson CJ. Regulation of IL-5 expression. Arch Immunol Ther Exp (Warsz). 2001; 49: 345-351.
13. Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008; 22: 1909-1917.
14. Shrier LA, Bowman FP, Lin M, et al. Mucosal immunity of the adolescent female genital tract. J Adolesc Health. 2003; 32: 183-186. (Pubitemid 36279402)
15. Al-Harthi L, Wright DJ, Anderson D, et al. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res. 2000; 20: 719-724. (Pubitemid 30636956)
16. Gargiulo AR, Fichorova RN, Politch JA, et al. Detection of implantationrelated cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles. Fertil Steril. 2004; 82 (suppl 3): 1226-1234. (Pubitemid 39335943)
17. Scott ME, Ma Y, Farhat S, et al. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol. 2006; 26: 222-232. (Pubitemid 43901651)
18. Myer L, Wright TC Jr, Denny L, et al. Nested case-control study of cervical mucosal lesions, ectopy, and incident HIV infection among women in Cape Town, South Africa. Sex Transm Dis. 2006; 33: 683-687. (Pubitemid 44632143)
19. Kaushic C, Ferreira VH, Kafka JK, et al. HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment. Am J Reprod Immunol. 2010; 63: 566-575.
20. Bollen LJ, Blanchard K, Kilmarx PH, et al. No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebocontrolled randomized clinical trial. J Acquir Immune Defic Syndr. 2008; 47: 253-257. (Pubitemid 351172195)
21. Anderson DJ, Williams DL, Ballagh SA, et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol. 2009; 61: 121-129.
22. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis. 2006; 193: 27-35. (Pubitemid 43032495)
23. Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception. 2006; 74: 133-140. (Pubitemid 44062469)
24. Roberts L, Passmore JA, Williamson C, et al. Genital tract inflammation in women participating in the CAPRISA TFV microbicide trial who became infected with HIV: a mechanism for breakthrough infection? Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27, 2011; Boston, MA.